Identification of novel kynurenine production-inhibiting benzenesulfonamide derivatives in cancer cells

Biochemical and Biophysical Research Communications

Volumn 419, Issue 3, 2012, Pages 556-561

  Nakano, Shintaro ^a   Takai, Kazushige ^a   Isaka, Yoshinobu ^a   Takahashi, Susumu ^a   Unno, Yuka ^a   Ogo, Naohisa ^a   Matsuno, Kenji ^a   Takikawa, Osamu ^b   Asai, Akira ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

Author keywords

Benzenesulfonamide; Indoleamine 2,3 dioxygenase (IDO); Kynurenine; Signal transducer and activator of transcription 1 (STAT1); Tryptophan

Indexed keywords

BENZENESULFONAMIDE DERIVATIVE; BENZYLISOTHIOUREA; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; MESSENGER RNA; STAT1 PROTEIN; UNCLASSIFIED DRUG; UREA DERIVATIVE;

ARTICLE; CANCER CELL; CATABOLISM; DNA BINDING; ENZYME ACTIVITY; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; SCREENING; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; ENZYME INHIBITORS; HELA CELLS; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KYNURENINE; SMALL MOLECULE LIBRARIES; STAT1 TRANSCRIPTION FACTOR; SULFONAMIDES;

ANIMALIA;

EID: 84858289016     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.02.059     Document Type: Article

References (22)

1. Stone T.W., Darlington L.G. Endogenous kynurenines as targets for drug discovery and development. Nat. Rev. Drug Discov. 2002, 1:609-620.
2. Munn D.H., Mellor A.L. IDO and tolerance to tumors. Trends Mol. Med. 2004, 10:15-18.
3. Munn D.H., Mellor A.L. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J. Clin. Invest. 2007, 117:1147-1154.
4. Lob S., Konigsrainer A., Rammensee H.G., Opelz G., Terness P. Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?. Nat. Rev. Cancer 2009, 9:445-452.
5. Rafice S.A., Chauhan N., Efimov I., Basran J., Raven E.L. Oxidation of l-tryptophan in biology: a comparison between tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase. Biochem. Soc. Trans. 2009, 37:408-412.
6. Uyttenhove C., Pilotte L., Theate I., Stroobant V., Colau D., Parmentier N., Boon T., Van den Eynde B.J. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 2003, 9:1269-1274.
7. Brandacher G., Perathoner A., Ladurner R., Schneeberger S., Obrist P., Winkler C., Werner E.R., Werner-Felmayer G., Weiss H.G., Gobel G., Margreiter R., Konigsrainer A., Fuchs D., Amberger A. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin. Cancer Res. 2006, 12:1144-1151.
8. Okamoto A., Nikaido T., Ochiai K., Takakura S., Saito M., Aoki Y., Ishii N., Yanaihara N., Yamada K., Takikawa O., Kawaguchi R., Isonishi S., Tanaka T., Urashima M. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin. Cancer Res. 2005, 11:6030-6039.
9. Opitz C.A., Litzenburger U.M., Sahm F., Ott M., Tritschler I., Trump S., Schumacher T., Jestaedt L., Schrenk D., Weller M., Jugold M., Guillemin G.J., Miller C.L., Lutz C., Radlwimmer B., Lehmann I., von Deimling A., Wick W., Platten M. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 2011, 478:197-203.
10. Muller A.J., DuHadaway J.B., Donover P.S., Sutanto-Ward E., Prendergast G.C. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat. Med. 2005, 11:312-319.
11. Yue E.W., Douty B., Wayland B., Bower M., Liu X., Leffet L., Wang Q., Bowman K.J., Hansbury M.J., Liu C., Wei M., Li Y., Wynn R., Burn T.C., Koblish H.K., Fridman J.S., Metcalf B., Scherle P.A., Combs A.P. Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model. J. Med. Chem. 2009, 52:7364-7367.
12. Liu X., Shin N., Koblish H.K., Yang G., Wang Q., Wang K., Leffet L., Hansbury M.J., Thomas B., Rupar M., Waeltz P., Bowman K.J., Polam P., Sparks R.B., Yue E.W., Li Y., Wynn R., Fridman J.S., Burn T.C., Combs A.P., Newton R.C., Scherle P.A. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood 2010, 115:3520-3530.
13. Koblish H.K., Hansbury M.J., Bowman K.J., Yang G., Neilan C.L., Haley P.J., Burn T.C., Waeltz P., Sparks R.B., Yue E.W., Combs A.P., Scherle P.A., Vaddi K., Fridman J.S. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors. Mol. Cancer Ther. 2010, 9:489-498.
14. Matsuno K., Takai K., Isaka Y., Unno Y., Sato M., Takikawa O., Asai A. S-Benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase. Bioorg. Med. Chem. Lett. 2010, 20:5126-5129.
15. Littlejohn T.K., Takikawa O., Skylas D., Jamie J.F., Walker M.J., Truscott R.J. Expression and purification of recombinant human indoleamine 2,3-dioxygenase. Protein Expr. Purif. 2000, 19:22-29.
16. Takikawa O., Kuroiwa T., Yamazaki F., Kido R. Mechanism of interferon-gamma action. Characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-gamma and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity. J. Biol. Chem. 1988, 263:2041-2048.
17. Uehara Y., Mochizuki M., Matsuno K., Haino T., Asai A. Novel high-throughput screening system for identifying STAT3-SH2 antagonists. Biochem. Biophys. Res. Commun. 2009, 380:627-631.
18. Darnell J.E., Kerr I.M., Stark G.R. JAK-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264:1415-1421.
19. Platanias L.C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 2005, 5:375-386.
20. Goh K.C., Haque S.J., Williams B.R. p38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons. EMBO J. 1999, 18:5601-5608.
21. Du M.X., Sotero-Esteva W.D., Taylor M.W. Analysis of transcription factors regulating induction of indoleamine 2,3-dioxygenase by IFN-gamma. J. Interferon Cytokine Res. 2000, 20:133-142.
22. Balachandran V.P., Cavnar M.J., Zeng S., Bamboat Z.M., Ocuin L.M., Obaid H., Sorenson E.C., Popow R., Ariyan C., Rossi F., Besmer P., Guo T., Antonescu C.R., Taguchi T., Yuan J., Wolchok J.D., Allison J.P., DeMatteo R.P. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of IDO. Nat. Med. 2011, 17:1094-1100.